BioLife Solutions, Inc. (BLFS)

BioLife Solutions announced preliminary Q4 and full year 2025 revenue, with full-year revenue exceeding guidance. A key executive announced their planned retirement. Several executives and Casdin Capital, LLC sold shares of company stock. BioLife Solutions' price target was raised, and it was named a 2026 top pick by Northland. The company completed the divestiture of its evo Cold Chain Logistics business for $25.5 million. BioLife Solutions reported Q3 2025 revenue of $28.1 million, a 31% year-over-year growth.

The provided search results do not contain explicit information regarding demand seasonality for BioLife Solutions' products and services. However, the company's financial performance is characterized by a robust revenue growth rate, indicating strong demand and market expansion. The company's focus on the cell and gene therapy market suggests a consistent underlying demand for its specialized biopreservation and cell processing tools.

BioLife Solutions, Inc. specializes in biopreservation and cold chain workflow solutions for the cell and gene therapy market, regenerative medicine, and advanced biologics. The company develops and markets cryopreservation media and technology platforms to maintain cell viability and functionality during processing, storage, and transport. Its major products include CryoStor, HypoThermosol, ThawSTAR system, Sexton cell processing product line, CellSeal cryogenic vials, and CryoCase. The company also provides technical support, training, and validation services.

BioLife Solutions serves a global customer base, including academic research centers, CDMOs, and biopharmaceutical companies. The company has distribution channels across North America, Europe, and Asia, with the majority of its revenue generated from the United States. Its products and services are available internationally, including in the United States, Europe, the Middle East, and Africa.

BioLife Solutions maintains a generally positive brand reputation, with a consensus rating of "Moderate Buy". MarketBeat evaluated BioLife Solutions as scoring higher than 69% of companies in the medical sector. Analyst sentiment is overwhelmingly positive, with 10 buy ratings and no hold or sell ratings as of February 2026. The company's strategic refocus on higher-margin cell-processing products and the divestiture of its evo Cold Chain business in October 2025 has shaped its reputation.

Institutional investors hold over 93% of BioLife Solutions' shares. Major institutional owners include Casdin Capital, LLC, BlackRock, Inc., T. Rowe Price Investment Management, Inc., Invesco Ltd., Vanguard Group Inc., and State Street Corp. Individual insiders own approximately 2.67% of the company's shares.